We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alexion Pharmaceuticals

News List

Alexion to buy biopharmaceutical firm Portola in $1.41bn deal pharmaceutical-business-review
May 06, 2020
Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn.
Wham! Alexion investors sucker-punched as PTO takes up Amgen's Soliris patent challenge fiercepharma
September 02, 2019
Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different.
Alexion Pharmaceuticals to File for FDA Approval of Soliris Successor in Mid-2018 biospace
April 28, 2018
Alexion Pharmaceuticals closed out its first quarter plans to seek regulatory approval for its paroxysmal nocturnal hemoglobinuria (PNH) treatment, ALXN1210
EU Commission Grants New Indication for Soliris for Refractory gMG pharmaceutical-technology
August 23, 2017
Alexion Pharmaceuticals announced the European Commission (EC) approved the extension of the indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR